WALTHAM, Mass., March 6, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX),a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will present at the Cowen 39th
A live webcast of the Company's presentation can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the events will also be available for a limited time.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company is developing its lead product candidate, entinostat, a once-weekly, oral, small molecule, class I HDAC inhibitor, in combination with exemestane and several approved PD-1/PD-(L)1 antagonists. The Company's pipeline also includes SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, as well as a portfolio of potent and selective inhibitors targeting the binding interaction of Menin with MLL-r, including its lead candidate SNDX-5613. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.
Investor ContactMelissa ForstArgot Partnersmelissa@argotpartners.comTel 212.600.1902
Media ContactDavid Rosen Argot Partners firstname.lastname@example.org Tel 212.600.1902
View original content:http://www.prnewswire.com/news-releases/syndax-to-present-at-the-cowen-39th-annual-health-care-conference-300807190.html
SOURCE Syndax Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!